Novartis Pharmaceuticals Corp., of East Hanover, N.J., part of Novartis AG, of Basel, Switzerland, said Phase III results showed that more than one-third of patients taking mTOR inhibitor Afinitor (everolimus) experienced a 50 percent or greater reduction in the size of their subependymal giant cell astrocytomas, noncancerous brain tumors associated with tuberous sclerosis. Data were presented at the TSC Research conference in Washington.